BRNS VS NVS Stock Comparison

Performance

BRNS
10/100

BRNS returned -42.40% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

NVS
100/100

NVS returned 11.56% in the last 12 months. Based on SPY's performance of -13.77%, its performance is above average giving it a score of 100 of 100.

Earnings

BRNS
100/100

BRNS has missed earnings 1 times in the last 20 quarters.

NVS
39/100

NVS has missed earnings 5 times in the last 20 quarters.

Volatility

BRNS
50/100

BRNS has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

NVS
44/100

NVS has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

Analyst Price Targets

BRNS

"Analyst Price Targets" not found for BRNS

NVS
67/100

3 analysts offer 12-month price targets for NVS. Together, they have an average target of 0, the most optimistic target put NVS at 0 within 12-months and the most pessimistic has NVS at 0.

Technicals

BRNS

"Technicals" not found for BRNS

NVS
10/100

NVS receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Profit

BRNS

"Profit" not found for BRNS

NVS
73/100

Out of the last 20 quarters, NVS has had 20 profitable quarters and has increased their profits year over year on 8 of them.

All score calculations are broken down here to help you make more informed investing decisions

Barinthus Biotherapeutics plc American Depositary Shares Summary

Nasdaq / BRNS

Healthcare

Biotechnology

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

Novartis AG Summary

New York Stock Exchange / NVS

Healthcare

Drug Manufacturers - General

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Power up your portfolio